Objective: Chronic heart failure (CHF) remains a major health problem, with high levels of
morbidity and mortality and a low health-related quality of life (HRQoL). We assessed the impact on
HRQoL of adding the If channel blocker, ivabradine, to a standard treatment regimen of patients with
ischaemic CHF (I-CHF) and heart rate (HR) ≥70 beats/min (bpm).
Methods: A randomized prospective study of 100 consecutive patients presenting with stable I-CHF, left ventricular ejection
fraction (LVEF) <40% and a sinus HR ≥70 bpm. New York Heart Association (NYHA) class, overall summary score
(OSS) and clinical summary score (CSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) were used to assess
HRQoL. The patients were randomized into 2 groups: carvedilol only (group I (n=50)) and carvedilol + ivabradine (group
II (n=50)). The patients were followed up for 12 weeks and their HRQoL scores were monitored and compared.
Results: The overall mean age of the cohort was 63±10 years with 70% (n=70) males. HRQoL scores had significantly
improved in group II after 12 weeks of follow-up. The net proportion of patients with a 5-point improvement in CSS was
30% higher in group II (p=0.002), whereas that for the OSS, it was 24% (p=0.001), when compared with group I. These
improvements were accompanied by a significant HR reduction (69 vs 78 bpm; p=0.002).
Conclusion: Adding ivabradine to the standard drug regimen, currently advocated by guidelines for CHF with a heart rate
≥70 bpm, resulted in a significant improvement in HRQoL.